Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar

blonca9
Oct 1, 2024
1 min read

The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor program, and a partnership on an alpha-particle radioligand platform. Plus, leadership advice and how technology has changed science.

Brought to you by:

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight